Gastroenterology review weighs GLP-1 receptor agonists for irritable bowel syndrome
Camilleri and Ford examine whether incretin drugs have a role in IBS, a condition with no approved peptide therapy.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 22 20:00 ETSource: Gastroenterology
The wire
- 01A Gastroenterology article by Camilleri, Ford and colleagues assesses the potential for GLP-1 receptor agonists in irritable bowel syndrome.
- 02Clinicians already field questions about off-label GLP-1 use for gut symptoms, and the class's known effect on gastric emptying cuts both ways in IBS.
- 03No approved indication exists; the piece is a review rather than new trial data, and prospective IBS trials would be needed to support use.
From the source
Read at pubmed.ncbi.nlm.nih.govPotential for GLP-1 Receptor Agonists in Irritable Bowel Syndrome
Gastroenterology · 2026 Oct 23 · Camilleri M, Ford AC et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42918357/
